Soleno Therapeutics Announces Regulatory Update on DCCR …
WEB5 hours ago · REDWOOD CITY, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a regulatory update from the U.S. Food and Drug Administration (FDA).
E-Star BioTech Set to Initiate Phase 2 Clinical Trial of MANP in ...
WEB5 hours ago · NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney diseases, today announced that it is set to initiate a Phase 2 clinical trial of MANP for the treatment of Resistant Hypertension supported by a recent round of financing.
Actualité des professionnels de santé | Santé log
WEB39€ TTC. / 7 Numéros. Format numérique. Format PDF ( revue imprimable ) Découvrez la revue. Santé log site dédié à l'actualité des professionnels de santé. Santé log apporte une information pertinente et de qualité sur l'actualité médicale.
T2 Biosystems Announces Preliminary Third Quarter 2024 Financial ...
WEB1 day ago · LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the third quarter 2024. Recent Financial and …
WeightWatchers Adds Compounded GLP-1, Expanding …
WEB5 hours ago · 1 Source: WeightWatchers internal data over a six month period. April - September 2024. 2 International Foundation of Employee Benefit Plans: GLP-1 Drugs: 2024 Pulse Survey Report U.S. Data 3 Source: WeightWatchers Spectrum Target Audience Study. Partnered with BSG. August 2024. 4 A compounded drug is “identical or nearly identical” if it and the FDA-approved drug have the same active ...
Autonomix Medical, Inc. to Participate in the 2024 Healthcare …
WEB5 hours ago · Live webcast fireside chat on Tuesday, October 15 th at 2:30 PM ET. THE WOODLANDS, TX, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, CEO of ...
Growth.Health Announces Launch of Powerful Data & Analytics …
WEB5 hours ago · ATLANTA, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Growth.Health today announced the launch of their powerful G1 Healthcare Data and Analytics Platform. The powerful SaaS engine is designed to leapfrog existing technologies serving the healthcare industry to yield unprecedented insights to allow every professional to more deeply understand their ...
Privia Health to Report Third Quarter 2024 Results on Thursday ...
WEB5 hours ago · ARLINGTON, Va., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its third quarter and nine-month periods ended September 30, 2024 before market open on Thursday, November 7, 2024. The press release is …
COVID-19 : Période d’incubation, dernières données | santé log
WEBle temps d'incubation moyen estimé de COVID-19 est de 5,1 jours ; pour 97,5% des personnes infectées, les symptômes sont apparus au plus tard le 11,5è jour ; moins de 2,5% des personnes infectées en moins de 2,2 jours ; le temps d’incubation avant apparition de la fièvre est estimé à 5,7 jours ; parmi 108 patients diagnostiqués en ...
COVID-19 : Pourquoi l’ivermectine fait toujours débat - santé log
WEBJul 31, 2022 · La découverte de failles méthodologiques dans une étude récente suggérant que le médicament réduit considérablement les décès liés au COVID-19 affaiblit aujourd’hui à nouveau les promesses de l'ivermectine, rouvre le débat et pose la question de données scientifiques viables en contexte d’urgence, comme pendant une pandémie.